When I last wrote about the makers of Byetta and Januvia, two leading diabetes drugs, I called them the Hatfields and McCoys of diabetes care.
Good call, that one.
The two manufacturers, Amylin (Byetta) and Merck (Januvia), are now out with dueling press releases each claiming their treatment is the best.
In theory, I can see both these drugs as winners, depending on the severity of the case as determined by physicians.
Financial analysts contacted by Forbes aren't buying it.
With no financial stake in this battle, I'm willing to let it go on, but Wall Street seems to want to declare Januvia a winner by knockout.
So, too, some lawyers.